HPV and RNA Binding Proteins: What We Know and What Remains to Be Discovered

被引:0
|
作者
Graham, Sheila V. [1 ]
机构
[1] Univ Glasgow, Sch Infect & Immun, Coll Med Vet & Life Sci, MRC Univ Glasgow Ctr Virus Res, Glasgow G61 1QH, Scotland
来源
VIRUSES-BASEL | 2024年 / 16卷 / 05期
关键词
Papillomaviruses; RNA binding proteins; RNA processing; epithelial differentiation; life cycle; HUMAN-PAPILLOMAVIRUS TYPE-16; NEGATIVE REGULATORY ELEMENT; LATE GENE-EXPRESSION; CELLULAR SPLICING FACTOR; DNA-DAMAGE RESPONSE; MESSENGER-RNA; L1; PROTEIN; U1; SNRNP; IN-VITRO; POLYADENYLATION ELEMENT;
D O I
10.3390/v16050783
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Papillomavirus gene regulation is largely post-transcriptional due to overlapping open reading frames and the use of alternative polyadenylation and alternative splicing to produce the full suite of viral mRNAs. These processes are controlled by a wide range of cellular RNA binding proteins (RPBs), including constitutive splicing factors and cleavage and polyadenylation machinery, but also factors that regulate these processes, for example, SR and hnRNP proteins. Like cellular RNAs, papillomavirus RNAs have been shown to bind many such proteins. The life cycle of papillomaviruses is intimately linked to differentiation of the epithelial tissues the virus infects. For example, viral late mRNAs and proteins are expressed only in the most differentiated epithelial layers to avoid recognition by the host immune response. Papillomavirus genome replication is linked to the DNA damage response and viral chromatin conformation, processes which also link to RNA processing. Challenges with respect to elucidating how RBPs regulate the viral life cycle include consideration of the orchestrated spatial aspect of viral gene expression in an infected epithelium and the epigenetic nature of the viral episomal genome. This review discusses RBPs that control viral gene expression, and how the connectivity of various nuclear processes might contribute to viral mRNA production.
引用
收藏
页数:17
相关论文
共 50 条
  • [21] Impact of HPV status on treatment of squamous cell cancer of the oropharynx: What we know and what we need to know
    Tribius, Silke
    Ihloff, Anna S.
    Rieckmann, Thorsten
    Petersen, Cordula
    Hoffmann, Markus
    CANCER LETTERS, 2011, 304 (02) : 71 - 79
  • [22] The origin of life: what we know, what we can know and what we will never know
    Pross, Addy
    Pascal, Robert
    OPEN BIOLOGY, 2013, 3
  • [23] Re: What we Know, What we Don't Know and What we Need to Know
    Wein, Alan J.
    JOURNAL OF UROLOGY, 2020, 203 (06): : 1068 - 1068
  • [24] FELINE IDIOPATHIC INFLAMMATORY BOWEL DISEASE What we know and what remains to be unraveled
    Jergens, Albert E.
    JOURNAL OF FELINE MEDICINE AND SURGERY, 2012, 14 (07) : 445 - 458
  • [25] COVID-19 Imaging: What We Know Now and What Remains Unknown
    Kanne, Jeffrey P.
    Bai, Harrison
    Bernheim, Adam
    Chung, Michael
    Haramati, Linda B.
    Kallmes, David F.
    Little, Brent P.
    Rubin, Geoffrey D.
    Sverzellati, Nicola
    RADIOLOGY, 2021, 299 (03) : E262 - E279
  • [26] Gut microbiome and Alzheimer's disease: What we know and what remains to be explored
    Kapoor, Bhupinder
    Biswas, Pratim
    Gulati, Monica
    Rani, Pooja
    Gupta, Reena
    AGEING RESEARCH REVIEWS, 2024, 102
  • [27] The gut microbiome in Alzheimer's disease: what we know and what remains to be explored
    Chandra, Sidhanth
    Sisodia, Sangram S.
    Vassar, Robert J.
    MOLECULAR NEURODEGENERATION, 2023, 18 (01)
  • [28] The gut microbiome in Alzheimer’s disease: what we know and what remains to be explored
    Sidhanth Chandra
    Sangram S. Sisodia
    Robert J. Vassar
    Molecular Neurodegeneration, 18
  • [29] Circulating RNA in Kidney Cancer: What We Know and What We Still Suppose
    Cinque, Alessandra
    Vago, Riccardo
    Trevisani, Francesco
    GENES, 2021, 12 (06)
  • [30] Nucleation and crystallization of globular proteins - What we know and what is missing
    Rosenberger, F
    Vekilov, PG
    Muschol, M
    Thomas, BR
    JOURNAL OF CRYSTAL GROWTH, 1996, 168 (1-4) : 1 - 27